- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 09.12. | ASH: Jaypirca matches Imbruvica in first-line CLL trial | ||
| 09.12. | ASH: FDA okays Gamida aplastic anaemia therapy as data drops | ||
| 08.12. | ASH: Gilead preps filing for anito-cel on iMMagine-1 data | ||
| 08.12. | ASH: Regeneron makes frontline case for Lynozyfic in myeloma | ||
| 08.12. | FDA reveals real-world pilot for digital health tools | ||
| 05.12. | CDC panel votes to scrap hepatitis B birth dose advice | ||
| 05.12. | Praxis soars on rare childhood epilepsy trial data | ||
| 05.12. | Protego's $130m for amyloidosis drug, and other financings | ||
| 05.12. | BMS's Breyanzi is first CAR-T for marginal zone lymphoma | ||
| 05.12. | Setback for MSD as German court blocks Keytruda SC launch | ||
| 05.12. | NHS use of digital cardiac rehab tools endorsed | ||
| 04.12. | NHS staff 'feel unprepared for digital transformation' | ||
| 04.12. | Lilly gets approval for earlier use of Jaypirca in CLL | ||
| 04.12. | FDA could hike user fees for ex-US drug programmes | ||
| 04.12. | Bayer takes Alport syndrome drug into phase 2 | ||
| 04.12. | Tracy Beth Hoeg will be fifth CDER head this year | ||
| 03.12. | Appeals court turns Enhertu patent dispute on its head | ||
| 03.12. | FDA clears trial of 'vectorised' ALS antibody from VectorY | ||
| 03.12. | AZ uses a priority review voucher for baxdrostat filing | ||
| 03.12. | FDA takes steps to limit non-human primate testing | ||
| 02.12. | Pazdur to leave FDA, shortly after taking CDER job | ||
| 02.12. | J&J gets EU approval for Imaavy in gMG | ||
| 02.12. | Bayer aims Mirena at women's health issue with no treatment | ||
| 02.12. | FDA doubles down on its push into AI | ||
| 02.12. | Slow recruitment still hitting UK trials, says pharma |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .